Prof Peter Brophy PhD

Professor

View graph of relations

Department of Biological, Environmental and Rural Sciences

Postal address
Aberystwyth University
Edward Llwyd Building
Penglais
Aberystwyth
United Kingdom of Great Britain and Northern Ireland
Contact
Phone: 01970 622332

Profile

Studied biochemistry at Glasgow and Stirling Universities before obtaining a PhD from Aberystwyth University on drug metabolism in parasitic worms. After holding a Medical Research Council research post at Aberystwyth (1987-1990) completed further research training in yeast biotechnology at the BioCentre in Leicester. In 1991 was awarded a Wellcome Trust Fellowship based at Nottingham University exploring parasite defences against immune assault. A Senior Research Fellowship in the Leicester Pharmacy School (1994-97) provided opportunities in rational drug design and lead compound synthesis. Established the first proteomics laboratory dedicated to parasitic worm investigations during Readerships at the Universities of Aberystwyth and Liverpool (1998-2006). In 2007 returned to Aberystwyth as a Professor in Parasitology. During  career has been an advisor in parasite drug discovery to WHO and has completed a number of industrial consultancies. To date, has supervised 20 PhD students and published a 100 plus research papers/books/chapters on parasitology, including the first experimental proteomics study in a parasitic worm and  resolved one of the first structures of a parasitic worm drug target.  Has held a number of research contracts to address  key problems in parasite control (anthelmintic resistance, vaccine, drug  and biomarker discovery).

Research interests

My main research interest is to resolve using functional genomics how liver and rumen fluke parasites interact with their respective host environments. To date, new parasite proteins have been discovered to support drug and vaccine development and diagnostics . I am also interested in developing new molecular tools to measure anthelmintic resistance in liver fluke and a protein biomarker panel has been identified to measure Triclabendazole (TCBZ) failure and resistance for new laboratory and faecal based field tests.

*